Answers are grounded in this paper and cite their sources.
Research reveals tumor debulking enhances durable remission rates in lymphoma with CAR T-cell therapy, suggesting new treatment strategies.
Summary: In this issue of Blood Cancer Discovery, Pomeroy and colleagues explore a population pharmacokinetic/pharmacodynamic model of axicabtagene ciloleucel in large B-cell lymphoma, quantifying how tumor debulking before chimeric antigen receptor (CAR) T-cell infusion can significantly improve durable remission rates. Their framework incorporates mechanistic modeling principles of CAR T-cell biology and therapy, such as CAR T-cell expansion, binding, killing, and stochastic CD19 loss, providing actionable insights for optimizing combination approaches and future trial design. See related article by Pomeroy and colleagues, p. XX
No takes yet. Share an insight, caveat, or question.
Philipp M. Altrock (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: